Quotient Sciences is pleased to announce that its Chief Scientific Officer, Dr. Andrew (Andy) Lewis, has joined the scientific advisory board for a new journal by the Royal Society of Chemistry – RSC Pharmaceutics.
In this role, Dr. Lewis will contribute to the success of the journal by advising on scientific topics of interest and other duties to promote the success of the journal. He will have the opportunity to contribute his own work to the journal, while also promoting its contents and encouraging new and existing readers to read and publish in the journal. Dr. Lewis will provide feedback and advise on the development of the journal to ensure it is positioned at the cutting edge of pharmaceutical science.
Earlier this year, Dr. Lewis was appointed to the role of Chief Scientific Officer for the company. He was also recognized by the Controlled Release Society (CRS) as a recipient of the 2024 Distinguished Service Award, which is given to CRS members in cases where an exceptional member fits the criteria for having given sustained and outstanding service, and inducted into the prestigious College of Fellows of the CRS for his significant contributions to the field of controlled release.
Andy has over 20 years of experience working in the pharmaceutical and biotech industry. His work has focused on advanced drug delivery technologies, particularly protein and peptide drug delivery, solubility enhancement, modified and controlled release.
"I look forward to joining the Advisory Board for RSC Pharmaceutics journal and supporting its development into a world-leading journal for pharmaceutical scientists. As a Gold Open Access journal, researchers publishing in it can be confident of a wide dissemination of their work to help build their reputation." – Dr. Andrew (Andy) Lewis